JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giannopoulou, E.
Right arrow Articles by Papadimitriou, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannopoulou, E.
Right arrow Articles by Papadimitriou, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

CELLULAR AND MOLECULAR

Amifostine Inhibits Angiogenesis in Vivo

Efstathia Giannopoulou, Panagiotis Katsoris, Dimitris Kardamakis, and Evangelia Papadimitriou

Laboratory of Molecular Pharmacology, Department of Pharmacy (E.G., E.P.); Division of Genetics, Cell & Developmental Biology, Department of Biology (P.K.); and Department of Radiation Oncology (D.K.), University of Patras, Patras, Greece.

Amifostine (WR-2721) is an inorganic thiophosphate-cytoprotective agent developed to selectively protect normal tissues against the toxicity of chemotherapy and radiation. We have previously shown that amifostine protects both chicken embryo chorioallantoic membrane (CAM) vessels and cells from the effects of X-rays. In the present work, we studied the effect of amifostine on angiogenesis in vivo, using the CAM model. Amifostine decreased the number of CAM vessels in a dose-dependent manner, without being toxic for the tissue. It also decreased the mRNA levels of both vascular endothelial growth factor (VEGF) isoforms VEGF165 and VEGF190, 6 and up to 48 h after its application onto the CAM. Similarly, it decreased the mRNA levels of inducible nitric-oxide synthase, 24 and 48 h after drug application. Furthermore, amifostine decreased the deposited amounts of laminin and collagen I 24 h after its application, without affecting the expression of the corresponding genes. The protein amounts and activity of matrix metalloproteinase-2 were not affected, whereas the expression of the corresponding gene was decreased up to 48 h after drug application. Finally, the activity of plasmin was increased 6 h after amifostine application and remained increased at later time points. These findings suggest that amifostine alters the expression of several molecules implicated in the angiogenesis process and affects the composition of the extracellular matrix in a way that leads to inhibition of angiogenesis. Such an antiangiogenic action of amifostine, together with its radioprotective effects, further supports its use in combination with radiotherapy for increased therapeutic efficacy.


Received August 6, 2002; accepted October 9, 2002.

Address correspondence to: Dr. E. Papadimitriou, Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, GR 26504 Greece. E-mail: epapad{at}upatras.gr




This article has been cited by other articles:


Home page
Evid Based Complement Alternat MedHome page
R. Chawla, R. Arora, S. Singh, R.K. Sagar, R. K. Sharma, R. Kumar, A. Sharma, R. P. Tripathi, S. C. Puri, H. A. Khan, et al.
Podophyllum hexandrum Offers Radioprotection by Modulating Free Radical Flux: Role of Aryl-Tetralin Lignans
Evid. Based Complement. Altern. Med., December 1, 2006; 3(4): 503 - 511.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.